Topics:

ASCO 2014 Brain Tumors

ASCO 2014 Brain Tumors

Cancer Network presents exclusive coverage of primary and metastatic brain tumors from the American Society of Clinical Oncology (ASCO) annual meeting. We'll bring you reports of the latest research, trials, and scientific advances that are changing the way brain tumors are managed and treated.

ASCO 2014 Brain Tumors

High-dose chemotherapy plus conventional radiotherapy resulted in a high 3-year overall survival in children and adolescents with newly diagnosed medulloblastoma and supratentorial primitive neuroectodermal tumor.

Addition of the drug armodafinil did not improve measures of fatigue in patients with gliomas undergoing treatment with radiotherapy, according to the results of a study presented at the 2014 ASCO Annual Meeting.

Researchers identified a six-gene signature that can help to predict the 3-year survival outcome for patients with grade II or grade III gliomas, independent of the patient’s histology, grade, and IDH1 mutations status.

A phase II trial evaluating the use of a dendritic cell vaccine, ICT-107, has shown that the immunotherapy had a positive effect on progression-free survival in patients with glioblastoma.

Positron emission tomography using [18]F-fluorothymidine as a tracer failed to distinguish true progression of glioblastoma from pseudoprogression in a small single-center study presented at the 2014 ASCO Annual Meeting.

As part of our coverage of the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, we discuss how molecular diagnosis in medulloblastoma affects clinical decision-making.

Subscribe to ASCO 2014 Brain Tumors on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.